Nuvama said investments topping ₹10,000 crore in new assets have diluted Aurobindo Pharma’s returns ratios. Previous Post PSU bank, auto stock gains lift Nifty above key 25,000 level Next Post HAL to build small satellite rockets after securing ISRO tech in ₹511 crore deal Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
